Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Androgen Antagonists. Found 28 abstracts

no pagination
Harshman LC, Chen YH, Liu G, Carducci MA, Jarrard D, Dreicer R, Hahn N, Garcia JA, Hussain M, Shevrin D, Eisenberger M, Kohli M, Plimack ER, Cooney M, Vogelzang NJ, Picus J, Dipaola R, Sweeney CJ. Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. J Clin Oncol. 2018 Feb;36(4):376-82.   PMCID: PMC5805480
Jung K, Park JC, Kang H, Brandes JC. Androgen deprivation therapy is associated with decreased second primary lung cancer risk in the United States veterans with prostate cancer. Epidemiology and health. 2018 Aug;40:e2018040.   PMCID: PMC6232654
Kishan AU, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Sandler KA, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Stephenson AJ, Klein EA, Song DY, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco S, Deville C, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR. Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer. Jama. 2018 Mar 06;319(9):896-905.   PMCID: PMC5885899
Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, Shevrin DH, Dreicer R, Hussain M, Eisenberger M, Kohli M, Plimack ER, Vogelzang NJ, Picus J, Cooney MM, Garcia JA, DiPaola RS, Sweeney CJ. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol. 2018 Apr 10;36(11):1080-7.   PMCID: PMC5891129
Hurwitz MD, Harris J, Sartor O, Xiao Y, Shayegan B, Sperduto PW, Badiozamani KR, Lawton CA, Horwitz EM, Michalski JM, Roof K, Beyer DC, Zhang Q, Sandler HM. Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621. Cancer. 2017 Jul;123(13):2489-96.   PMCID: PMC5474197
Kishan AU, Shaikh T, Wang PC, Reiter RE, Said J, Raghavan G, Nickols NG, Aronson WJ, Sadeghi A, Kamrava M, Demanes DJ, Steinberg ML, Horwitz EM, Kupelian PA, King CR. Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. Eur Urol. 2017 May;71(5):766-73.
Lawton CA, Lin X, Hanks GE, Lepor H, Grignon DJ, Brereton HD, Bedi M, Rosenthal SA, Zeitzer KL, Venkatesan VM, Horwitz EM, Pisansky TM, Kim H, Parliament MB, Rabinovitch R, Roach M, Kwok Y, Dignam JJ, Sandler HM. Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202. Int J Radiat Oncol Biol Phys. 2017 Jun;98(2):296-303.   PMCID: PMC5603177
Mirhadi AJ, Zhang Q, Hanks GE, Lepor H, Grignon DJ, Peters CA, Rosenthal SA, Zeitzer K, Radwan JS, Lawton C, Parliament MB, Reznik RS, Sandler HM. Effect of Long-Term Hormonal Therapy (vs Short-Term Hormonal Therapy): A Secondary Analysis of Intermediate-Risk Prostate Cancer Patients Treated on NRG Oncology RTOG 9202. Int J Radiat Oncol Biol Phys. 2017 Mar;97(3):511-5.   PMCID: PMC5485922
Pollack A, Kwon D, Walker G, Khor LY, Horwitz EM, Buyyounouski MK, Stoyanova R. Prospective Validation of Diagnostic Tumor Biomarkers in Men Treated With Radiotherapy for Prostate Cancer. Journal of the National Cancer Institute. 2017 Feb;109(2):1-8.   PMCID: PMC6075027
Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. The New England journal of medicine. 2015 Aug 20;373(8):737-46.   PMCID: 4562797
Pollack A, Dignam JJ, Diaz DA, Wu Q, Stoyanova R, Bae K, Dicker AP, Sandler H, Hanks GE, Feng FY. A Tissue Biomarker-Based Model That Identifies Patients with a High Risk of Distant Metastasis and Differential Survival by Length of Androgen Deprivation Therapy in RTOG Protocol 92-02. Clinical Cancer Research. 2014 Dec;20(24):6379-88.   PMCID: 4299458
Hensley HH, Hannoun-Levi JM, Hachem P, Mu Z, Stoyanova R, Khor LY, Agrawal S, Pollack A. PKA knockdown enhances cell killing in response to radiation and androgen deprivation. International journal of cancer. 2011 Feb 15;128(4):962-73.   PMCID: NIHMS236076
Buyyounouski MK. Androgen deprivation therapy in high-risk prostate cancer. Oncology (Williston Park). 2010 Aug;24(9):806, 809.   PMCID: Not NIH funded
Khor LY, Bae K, Paulus R, Al-Saleem T, Hammond ME, Grignon DJ, Che M, Venkatesan V, Byhardt RW, Rotman M, Hanks GE, Sandler HM, Pollack A. MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02. J Clin Oncol. 2009 Jul;27(19):3177-84.   PMCID: PMC2716939
Abramowitz MC, Pollack A. Postprostatectomy radiation therapy for prostate cancer. Semin Radiat Oncol. 2008 Jan;18(1):15-22.
Held-Warmkessel J. Caring for a patient with metastatic prostate cancer. Nursing. 2008 Jun;38(6):52-6.
Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD, Venkatesan V, Lawton CA, Rosenthal SA, Sandler HM, Shipley WU. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol. 2008 May 20;26(15):2497-504.
Mu Z, Hachem P, Hensley H, Stoyanova R, Kwon HW, Hanlon AL, Agrawal S, Pollack A. Antisense MDM2 enhances the response of androgen insensitive human prostate cancer cells to androgen deprivation in vitro and in vivo. The Prostate. 2008 May;68(6):599-609.
Eade TN, Al-Saleem T, Horwitz EM, Buyyounouski MK, Chen DY, Pollack A. Role of radiotherapy in ductal (endometrioid) carcinoma of the prostate. Cancer. 2007 May 15;109(10):2011-5.
Konski A, Watkins-Bruner D, Feigenberg S, Hanlon A, Kulkarni S, Beck JR, Horwitz EM, Pollack A. Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer. Int J Radiat Oncol Biol Phys. 2006 Aug;66(2):408-15.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Androgen Antagonists

Prostatic Neoplasms Male Androgen Antagonists therapeutic use Aged pathology mortality Middle Aged therapy 80 and over Aged drug therapy Treatment Outcome Combined Modality Therapy blood Neoplasm Metastasis Adult Prostate-Specific Antigen Follow-Up Studies methods Adenocarcinoma Prostatectomy Neoplasm Grading Time Factors radiotherapy adverse effects Retrospective Studies Prognosis Hormonal Antineoplastic Agents metabolism Kaplan-Meier Estimate Neoplasm Staging administration & dosage Radiotherapy Conformal Radiotherapy Proto-Oncogene Proteins c-mdm2 genetics Disease-Free Survival Antineoplastic Agents Tumor Suppressor Protein p53 Tumor Biomarkers Treatment Failure Xenograft Model Antitumor Assays agonists Proportional Hazards Models Taxoids Mice Apoptosis Nude Mice Docetaxel Intensity-Modulated Radiotherapy Hormone-Dependent Neoplasms Brachytherapy Kallikreins Cell Proliferation Ki-67 Antigen analysis epidemiology statistics & numerical data Androgen Receptors Antineoplastic Combined Chemotherapy Protocols Gonadotropin-Releasing Hormone Multivariate Analysis chemically induced Risk Survival Rate chemotherapy Randomized Controlled Trials as Topic Palliative Care Decision Support Techniques Prospective Studies Patient Education as Topic biosynthesis drug effects Social Support Psychological Adaptation Radiotherapy Dosage Quality-Adjusted Life Years Phase III Clinical Trials as Topic Markov Chains Combination Drug Therapy United States Neutropenia radiation effects androgen deprivation Androgen antagonists diagnosis docetaxel economics Goserelin Cyclic AMP-Dependent Protein Kinases Oncologic Nursing inhibitors Cyclin-Dependent Kinase Inhibitor p16 Gleason 10 Risk Factors chemistry pharmacology Hormones Neoplasm Invasiveness Forecasting Cardiovascular Diseases secondary radiation Second Primary Neoplasms Inbred BALB C Mice antagonists & Ductal Carcinoma Factual Databases Proton Therapy Adjuvant Radiotherapy Lung neoplasms Prostatic neoplasms Health Care Costs control prevention & control Tumor Cell Line Cause of Death Computer-Assisted Image Interpretation Drug Administration Schedule Antisense Oligonucleotides Prostate Gene Expression psychology prevention & Tumor Stem Cell Assay Nurse's Role Nursing Assessment ROC Curve Radical prostatectomy Cost-Benefit Analysis Empathy Mass Screening Lung Neoplasms bcl-2-Associated X Protein Propensity Score Orchiectomy Cyclooxygenase 2 Nitriles Immunoenzyme Techniques Androgens Western Blotting Survival Analysis high risk Disease Progression Antisense Oligodeoxyribonucleotides Area Under Curve Tosyl Compounds Flutamide Adjuvant Chemoradiotherapy Proto-Oncogene Proteins p21(ras)
Last updated on Friday, July 10, 2020